Accretion Nutraveda
270.00
-12.00(-4.26%)
Market Cap₹195.51 Cr
PE Ratio-
IndustryHealthcare
Company Performance:
1D-4.26%
1M-9.70%
6M0.00%
1Y0.00%
5Y0.00%
View Company Insightsright
More news about Accretion Nutraveda
01May 26
Accretion Nutraveda Limited Schedules Board Meeting for May 8, 2026 to Approve FY26 Financial Results
Accretion Nutraveda Limited has scheduled a Board of Directors meeting for May 8, 2026, to consider and approve audited financial results for the year ended March 31, 2026. The company communicated this intimation to BSE Limited on May 1, 2026, complying with Regulation 29 of SEBI LODR 2015. The meeting represents standard corporate governance practice for the BSE-listed company with scrip code 544694.
 no imag found
04Apr 26
Accretion Nutraveda Limited Files SEBI Compliance Certificate for Q4FY26
Accretion Nutraveda Limited submitted its mandatory SEBI compliance certificate for Q4FY26, confirming all company shares remained in dematerialized form during the quarter ended 31st March, 2026. The certificate, issued by registrar KFin Technologies Limited under Regulation 74(5) of SEBI (Depositories and Participants) Regulation, 2018, reported no rematerialization requests during the period. This regulatory filing maintains the company's transparency obligations and demonstrates continued compliance with SEBI depositories regulations.
 no imag found
01Apr 26
Accretion Nutraveda Limited Updates Corporate Identification Number Following BSE SME Listing
Accretion Nutraveda Limited has notified BSE Limited about the update of its Corporate Identification Number from U24290GJ2021PLC121216 to L24290GJ2021PLC121216, following its equity shares listing on BSE SME Exchange on 04th February, 2026. The Gujarat-based company, incorporated in 2021, maintains an authorised capital of ₹8,00,00,000 and paid-up capital of ₹7,24,00,000. The CIN update was processed by the Ministry of Corporate Affairs as part of the post-listing regulatory requirements.
 no imag found
26Mar 26
Accretion Nutraveda Limited Appoints KMV & Co as Internal Auditor and Authorizes Key Personnel for SEBI Disclosures
Accretion Nutraveda Limited's board meeting on March 26, 2026 resulted in the appointment of M/s. KMV & Co., Chartered Accountants as Internal Auditor and authorization of key managerial personnel for SEBI compliance. The firm brings expertise in audit, taxation, and outsourcing services with presence across multiple cities.
 no imag found
Accretion Nutraveda
270.00
-12.00
(-4.26%)
1 Year Returns:0.00%
Industry Peers
Sun Pharmaceutical
1,840.00
(-1.13%)
Divis Laboratories
9,322.00
(-1.23%)
Torrent Pharmaceuticals
4,965.50
(+0.72%)
Zydus Life Science
1,119.10
(+0.12%)
Cipla
1,366.00
(-0.53%)
Laurus Labs
1,969.00
(+1.23%)
Dr Reddys Laboratories
1,165.50
(+1.97%)
Aurobindo Pharma
1,679.80
(+0.68%)
Lupin
2,095.00
(+0.83%)
Mankind Pharma
2,280.00
(+1.86%)